Many patients with advanced lung cancer carry at least one of the known driver mutations - KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, NRAS, or oncogenic changes - ALK rearrangements and MET amplifications. But if you perform genetic testing on tumor biopsies at the time of diagnosis, you can have a pretty good idea if there's an 'oncogene addiction' of certain type that will most likely respond to a targeted therapy for some time (until resistance emerges).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.